Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Northcott

Showing results (131-140 of 223) with videos related to

Pageof 23
Sort By:
Acta Neuropathologica|May 12, 2019
Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypesTanvi Sharma, Edward C Schwalbe, Daniel Williamson, et al.
Biorxiv : the Preprint Server for Biology|May 27, 2024
KBTBD4 Cancer Hotspot Mutations Drive Neomorphic Degradation of HDAC1/2 Corepressor ComplexesXiaowen Xie, Olivia Zhang, Megan J R Yeo, et al.
The American Journal of Pathology|September 19, 2012
The RNA-binding protein Musashi1 affects medulloblastoma growth via a network of cancer-related genes and is an indicator of poor prognosisDat T Vo, Dharmalingam Subramaniam, Marc Remke, et al.
Acta Neuropathologica|October 25, 2013
Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous systemChristian Koelsche, Felix Sahm, David Capper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2011
FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastomaMarc Remke, Thomas Hielscher, Andrey Korshunov, et al.
Cancer Cell|February 21, 2012
An animal model of MYC-driven medulloblastomaYanxin Pei, Colin E Moore, Jun Wang, et al.
Acta Neuropathologica|December 23, 2019
Correction to: Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trialsAnthony P Y Liu, Brian Gudenas, Tong Lin, et al.
Nature|February 12, 2025
Converging mechanism of UM171 and KBTBD4 neomorphic cancer mutationsXiaowen Xie, Olivia Zhang, Megan J R Yeo, et al.
Nature Communications|May 26, 2022
Author Correction: scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapyJennifer Karin Ocasio, Benjamin Babcock, Daniel Malawsky, et al.
Nature Communications|December 22, 2019
scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapyJennifer Karin Ocasio, Benjamin Babcock, Daniel Malawsky, et al.
Pageof 23

Showing results (131-140 of 223) with videos related to

Sort By:
Pageof 23
Acta Neuropathologica|May 12, 2019
Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypesTanvi Sharma, Edward C Schwalbe, Daniel Williamson, et al.
Biorxiv : the Preprint Server for Biology|May 27, 2024
KBTBD4 Cancer Hotspot Mutations Drive Neomorphic Degradation of HDAC1/2 Corepressor ComplexesXiaowen Xie, Olivia Zhang, Megan J R Yeo, et al.
The American Journal of Pathology|September 19, 2012
The RNA-binding protein Musashi1 affects medulloblastoma growth via a network of cancer-related genes and is an indicator of poor prognosisDat T Vo, Dharmalingam Subramaniam, Marc Remke, et al.
Acta Neuropathologica|October 25, 2013
Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous systemChristian Koelsche, Felix Sahm, David Capper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2011
FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastomaMarc Remke, Thomas Hielscher, Andrey Korshunov, et al.
Cancer Cell|February 21, 2012
An animal model of MYC-driven medulloblastomaYanxin Pei, Colin E Moore, Jun Wang, et al.
Acta Neuropathologica|December 23, 2019
Correction to: Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trialsAnthony P Y Liu, Brian Gudenas, Tong Lin, et al.
Nature|February 12, 2025
Converging mechanism of UM171 and KBTBD4 neomorphic cancer mutationsXiaowen Xie, Olivia Zhang, Megan J R Yeo, et al.
Nature Communications|May 26, 2022
Author Correction: scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapyJennifer Karin Ocasio, Benjamin Babcock, Daniel Malawsky, et al.
Nature Communications|December 22, 2019
scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapyJennifer Karin Ocasio, Benjamin Babcock, Daniel Malawsky, et al.
Pageof 23